Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
epidermal growth factor receptor-targeting third-generation chimeric antigen receptor t-cell + small molecule inhibitor
- Development stage
- Preclinical
- Lead developer
- National Institute of Diagnostics and Vaccine Development in Infectious Diseases
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Small Molecules
- Administration
- Intravenous
01
Overview
This preclinical combination therapy, developed by the National Institute of Diagnostics and Vaccine Development in Infectious Diseases (NIDVD) at Xiamen University, pairs third-generation chimeric antigen receptor T-cells (CAR-T) with a small molecule inhibitor of epigenetic modifiers. The CAR-T cells are engineered to target the epidermal growth factor receptor (EGFR) using a cetuximab-derived single-chain variable fragment (scFv) and contain a tripartite signaling domain consisting of CD28, 4-1BB, and CD3ζ. The therapy is primarily aimed at treating solid tumors, specifically triple-negative breast cancer (TNBC), where EGFR is frequently overexpressed. The addition of the small molecule inhibitor is designed to overcome CAR-T resistance by preventing the epigenetic remodeling and enhancer activation that leads to the expression of immunosuppressive genes in tumor cells.
- Other names
- EGFR 3rd-gen CAR-T (combination)EGFR-targeting 3rd-gen CAR-T + epigenetic modifier inhibitor
02
Targets
EGFR (Epidermal growth factor receptor)EGFRvIII (Epidermal growth factor receptor variant III)
Beyond the preview
Go deeper on epidermal growth factor receptor-targeting third-generation chimeric antigen receptor t-cell + small molecule inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on epidermal growth factor receptor-targeting third-generation chimeric antigen receptor t-cell + small molecule inhibitor.